Edition:
United Kingdom

Zealand Pharma A/S (ZELA.CO)

ZELA.CO on Copenhagen Stock Exchange

118.00DKK
18 Sep 2018
Change (% chg)

kr.3.80 (+3.33%)
Prev Close
kr.114.20
Open
kr.114.00
Day's High
kr.127.00
Day's Low
kr.113.20
Volume
918,501
Avg. Vol
114,687
52-wk High
kr.127.00
52-wk Low
kr.78.50

Chart for

About

Zealand Pharma A/S is a Denmark-based biopharmaceutical company engaged in the discovery, development and commercialization of peptide-based medicines. The Company's pipeline comprises two implementation areas: Cardio-metabolic diseases and Other indications. The Cardio-metabolic diseases area includes medicines for diabetes and... (more)

Overall

Beta: 0.84
Market Cap(Mil.): kr.3,751.36
Shares Outstanding(Mil.): 30.75
Dividend: --
Yield (%): --

Financials

  ZELA.CO Industry Sector
P/E (TTM): -- 85.68 32.76
EPS (TTM): -4.08 -- --
ROI: -26.95 1.78 14.61
ROE: -67.92 3.29 16.33

BRIEF-Zealand Q1 Net Sales Of Soliqua 100/33 And Lyxumia/Adlyxin At EUR 14.5 Mln

* REG-ZEALAND ANNOUNCES NET SALES OF SOLIQUA® 100/33 AND LYXUMIA®/ADLYXIN® FOR THE FIRST QUARTER OF 2018

27 Apr 2018

BRIEF-Zealand Announces Successful End-Of-Phase 2 Meeting With FDA On Glepaglutide For Short Bowel Syndrome

* ZEALAND ANNOUNCES SUCCESSFUL END-OF-PHASE 2 MEETING WITH FDA ON GLEPAGLUTIDE FOR SHORT BOWEL SYNDROME

26 Apr 2018

BRIEF-Zealand And Roche Diabetes Care Enter Phase 3 Study Collaboration For Treatment Of Congenital Hyperinsulinism With Dasiglucagon

April 11 Zealand Pharma A/S - Co Is Responsible For Conducting Phase 3 Trials, While Roche Diabetes Care Provides Its Accu :

11 Apr 2018

BRIEF-Zealand Pharma Enters Collaboration Agreement With Roche Diabetes Care

* HAS ENTERED A COLLABORATION AGREEMENT WITH ROCHE DIABETES CARE

11 Apr 2018

BRIEF-Zealand Pharma: Positive Results From First Phase 3 Trial For Treatment Of Severe Hypoglycemia

* REG-ZEALAND PHARMA'S FIRST PHASE 3 TRIAL WITH DASIGLUCAGON FOR TREATMENT OF SEVERE HYPOGLYCEMIA SUCCESSFULLY MEETS ITS PRIMARY OBJECTIVE

20 Mar 2018

Earnings vs. Estimates